TG-1101

TG Therapeutics shares rocket up on successful PhIII leukemia study, teeing up a shot at accelerated FDA OK
Endpoints
Mon, 03/6/17 - 09:47 am
TG Therapeutics
ublituximab
TG-1101
FDA
CLL